

ALUNBRIG® is indicated as

monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC) previously not treated with an ALK inhibitor.

ALUNBRIG® is indicated as

monotherapy for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

ALUNBRIG (BRIGATINIB) AVAILABLE NOW

Reference: Alunbrig® Malaysia Approved Professional Information, June 2020.

For Healthcare Professionals Only.



SCAN HERE

for ALUNBRIG® Abbreviated Prescribing Information



ONCOLOGY

Takeda Malaysia Sdn Bhd (868989-K) Unit TB-L13-1, Level 13, Tower B Plaza 33, No.1, Jalan Kemajuan Seksyen 13, 46200 Petaling Jaya. Selangor Darul Ehsan, Malaysia.

Copyright © 2023 Takeda Pharmaceutical Company Limited. all rights reserved. Takeda and the Takeda Logo are trademarks of Takeda Pharmaceutical Company Limited.